Sign in

    Alex Sanagathon • Tuist Securities

    Alex Sanagathon is a Vice President and Equity Research Analyst at Tuist Securities, specializing in financial sector research with a focus on regional banks and fintech firms. He covers companies including Regions Financial, First Republic Bank, and Square, and is recognized for maintaining an investment recommendation success rate of approximately 68% on major analyst platforms, with a strong track record of delivering above-benchmark returns for clients. Sanagathon began his financial services career in 2013 as an equity research associate at Janus Investment Group, progressing through roles at William Blair and Raymond James before joining Tuist Securities in 2021. He is a FINRA-registered representative, holding the Series 7, 63, and 86/87 licenses, and has been noted for his ability to identify emerging trends within the fintech landscape.

    Alex Sanagathon's questions to Kyverna Therapeutics Inc (KYTX) leadership

    Alex Sanagathon's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q3 2024

    Question

    Speaking for Crepa de Veraconda, Alex Sanagathon asked if the TIC2 degrader (KT295) could address efficacy challenges seen with inhibitors in IBD and whether the company would enroll TIC2 inhibitor-experienced patients in future trials.

    Answer

    Founder, President, and CEO Nellie Monofi stated that the degrader's goal is to be transformative by fully removing the TIC2 protein, which should deliver superior efficacy to partial inhibitors. Chief Medical Officer Jared Gullop added that while they would not initially enroll patients who progressed on prior inhibitors, they might consider it in later studies.

    Ask Fintool Equity Research AI